UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 2199-13
Program Prior Authorization/Medical Necessity
Medication Kevzara® (sarilumab) Injection
P&T Approval Date 5/2020, 5/2021, 6/2021, 12/2021, 11/2022, 1/2023, 4/2023, 7/2023,
2/2024, 8/2024, 10/2024, 4/2025, 6/2025
Effective Date 9/1/2025
1. Background:
Kevzara (sarilumab) is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of
adult patients with moderately to severely active rheumatoid arthritis who have had an
inadequate response or intolerance to one or more disease-modifying antirheumatic drugs
(DMARDs) 1. Examples of DMARDs commonly used in the treatment of rheumatoid arthritis
include methotrexate, leflunomide, and sulfasalazine.2,3 Kevzara is also indicated for the
treatment of adult patients with polymyalgia rheumatica (PMR) who have had an inadequate
response to corticosteroids or who cannot tolerate corticosteroid taper and for the treatment of
patients who weigh 63 kg or greater with active polyarticular juvenile idiopathic arthritis (pJIA).
2. Coverage Criteriaa:
A. Rheumatoid Arthritis (RA)
1. Initial Authorization
a. Kevzara will be approved based on all of the following criteria:
(1) Diagnosis of moderately to severely active rheumatoid arthritis
-AND-
(2) One of the following:
(a) All of the following:
i. One of the following:
a. History of failure to a 3 month trial of one non-biologic disease
modifying anti-rheumatic drug (DMARD) [e.g., methotrexate,
leflunomide, sulfasalazine, hydroxychloroquine] at maximally
indicated doses, unless contraindicated or clinically significant
adverse effects are experienced (document drug, date, and duration of
trial)b
-OR-
b. Patient has been previously treated with a targeted immunomodulator
FDA-approved for the treatment of rheumatoid arthritis as
© 2025 UnitedHealthcare Services, Inc.
1
documented by claims history or submission of medical records
(Document drug, date, and duration of therapy) [e.g., adalimumab,
Cimzia (certolizumab), Enbrel (etanercept), Olumiant (baricitinib),
Orencia (abatacept), Rinvoq (upadacitinib), Simponi (golimumab),
Xeljanz/Xeljanz XR (tofacitinib)]
-AND-
ii. History of failure, contraindication, or intolerance to two of the following
preferred products (Document drug, date, and duration of trial):
a. One of the preferred adalimumab productsc
b. Cimzia (certolizumab)
c. Enbrel (etanercept)
d. Rinvoq (upadacitinib)
e. Simponi (golimumab)
f. Xeljanz/Xeljanz XR (tofacitinib)
-AND-
iii. History of failure, contraindication, or intolerance to both of the
following preferred products (Document drug, date, and duration of
trial):
a. Actemra (tocilizumab) or Tyenne (tocilizumab-aazg)
b. Orencia (abatacept)
-OR-
(b) Both of the following:
i. Patient is currently on Kevzara therapy as documented by claims history
or submission of medical records (Document date and duration of
therapy):
-AND-
ii. Patient has not received a manufacturer supplied sample at no cost in
the prescriber’s office, or any form of assistance from the Sanofi and
Regeneron sponsored KevzaraConnect® (e.g., sample card which can
be redeemed at a pharmacy for a free supply of medication) as a
means to establish as a current user of Kevzara*
-AND-
(3) Patient is not receiving Kevzara in combination with another targeted
immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel
(etanercept), Olumiant (baricitinib), Orencia (abatacept), Rinvoq
(upadacitinib), Simponi (golimumab), Xeljanz/Xeljanz XR (tofacitinib)]
© 2025 UnitedHealthcare Services, Inc.
2
-AND-
(4) Prescribed by or in consultation with a rheumatologist
* Patients requesting initial authorization who were established on therapy via the receipt of a
manufacturer supplied sample at no cost in the prescriber’s office or any form of assistance
from the Sanofi and Regeneron sponsored KevzaraConnect® shall be required to meet
initial authorization criteria as if patient were new to therapy.
Authorization will be issued for 12 months.
2. Reauthorization
a. Kevzara will be approved based on all of the following criteria:
(1) Documentation of positive clinical response to Kevzara therapy
-AND-
(2) Patient is not receiving Kevzara in combination with another targeted
immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel
(etanercept), Olumiant (baricitinib), Orencia (abatacept), Rinvoq
(upadacitinib), Simponi (golimumab), Xeljanz/Xeljanz XR (tofacitinib)]
Authorization will be issued for 12 months.
B. Polymyalgia Rheumatica (PMR)
1. Initial Authorization
a. Kevzara will be approved based on all of the following criteria:
(1) Diagnosis of polymyalgia rheumatica (PMR)
-AND-
(2) Patient has had an inadequate response to corticosteroids or cannot tolerate
corticosteroid taper^
-AND-
(3) Patient is not receiving Kevzara in combination with another targeted
immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel
(etanercept), Olumiant (baricitinib), Orencia (abatacept), Rinvoq
(upadacitinib), Simponi (golimumab), Xeljanz/Xeljanz XR (tofacitinib)]
-AND-
(4) Prescribed by or in consultation with a rheumatologist
© 2025 UnitedHealthcare Services, Inc.
3
Authorization will be issued for 12 months.
2. Reauthorization
a. Kevzara will be approved based on both of the following criteria:
(1) Documentation of positive clinical response to Kevzara therapy
-AND-
(2) Patient is not receiving Kevzara in combination with another targeted
immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel
(etanercept), Olumiant (baricitinib), Orencia (abatacept), Rinvoq
(upadacitinib), Simponi (golimumab), Xeljanz/Xeljanz XR (tofacitinib)]
Authorization will be issued for 12 months.
C. Polyarticular Juvenile Idiopathic Arthritis (pJIA)
1. Initial Authorization
a. Kevzara will be approved based on all of the following criteria:
(1) Diagnosis of active polyarticular juvenile idiopathic arthritis
-AND-
(2) Patient is not receiving Kevzara in combination with another targeted
immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel
(etanercept), Olumiant (baricitinib), Orencia (abatacept), Rinvoq
(upadacitinib), Simponi (golimumab), Xeljanz/Xeljanz XR (tofacitinib)]
-AND-
(3) Prescribed by or in consultation with a rheumatologist
Authorization will be issued for 12 months.
2. Reauthorization
a. Kevzara will be approved based on both of the following criteria:
(1) Documentation of positive clinical response to Kevzara therapy
-AND-
(2) Patient is not receiving Kevzara in combination with another targeted
immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel
(etanercept), Olumiant (baricitinib), Orencia (abatacept), Rinvoq
(upadacitinib), Simponi (golimumab), Xeljanz/Xeljanz XR (tofacitinib)]
© 2025 UnitedHealthcare Services, Inc.
4
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
b For Connecticut, Kentucky and Mississippi business only a 30-day trial will be required.
c For a list of preferred products please reference drug coverage tools.
^Tried/failed alternative(s) are supported by FDA labeling.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Kevzara [package insert]. Bridgewater, NJ: Sanofi-Aventis.; February 2023.
2. Pavy S. Constantin A, Pham T, et al. Methotrexate therapy for rheumatoid arthritis: clinical
practice guidelines based on published evidence and expert opinions. Joint Bone Spine
2006;73(4):388-95.
3. Singh JA, Saag KG, Bridges SL, et al. 2015 American College of Rheumatology Guideline
for the Treatment of Rheumatoid Arthritis. Arthritis Care & Research. Arthritis Rheum.
2016;68(1):1-26.
Program Prior Authorization/Medical Necessity – Kevzara (sarilumab)
Change Control
5/2020 New program.
5/2021 Annual review. Removed prescriber requirement from reauthorization
criteria.
6/2021 Added coverage criteria for patients previously treated with a biologic
DMARD. Added clarification that submission of medical records is
required documenting current therapy with Kevzara in order to bypass
step if claim history not available.
12/2021 Updated conventional DMARD bypass language for rheumatoid
arthritis with no change to clinical intent. Updated CT/KY footnote.
11/2022 Added Enbrel as a preferred product step option. Added Enbrel as an
example where appropriate. Added Mississippi to state mandate
footnote.
1/2023 Updated step therapy requirements to Humira or Amjevita. Updated
listed examples from Humira to adalimumab.
4/2023 Updated step therapy requirement from Humira or Amjevita to one of
the preferred adalimumab products and added the footnote “For a list of
preferred adalimumab products please reference drug coverage tools.”
Added coverage criteria for polymyalgia rheumatica. Added Rinvoq as
an example where appropriate. Updated background and references.
© 2025 UnitedHealthcare Services, Inc.
5
7/2023 Updated not receiving in combination language to targeted
immunomodulator and updated examples.
2/2024 Removed Olumiant as a preferred product for RA. Updated state
mandate footnote to 30-day trial for Connecticut.
8/2024 Added clinical coverage criteria for pJIA. Updated background and
reference. Alphabetized preferred products and targeted
immunomodulator examples with no change to intent.
10/2024 Updated RA step requirement noting Adalimumab-adaz (unbranded
Hyrimoz), Amjevita for Nuvaila, and Humira as preferred adalimumab
products with no change to clinical intent. Removed preferred
adalimumab footnote.
4/2025 Removed examples for adalimumab step therapy. Added the footnote
“For a list of preferred products please reference drug coverage tools.”
6/2025 Added “Actemra or Tyenne” to step criteria where applicable.
© 2025 UnitedHealthcare Services, Inc.
6